Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label trial of tislelizumab added to total neoadjuvant treatment for locally advanced rectal cancer
MOH_2024-11-14_013511Phase 2Recruiting
- Sponsor
- פרופ' ברוך ברנר, המרכז הרפואי רבין
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab in rectal cancer (2 arms), sponsored by פרופ' ברוך ברנר, המרכז הרפואי רבין. Primary endpoint: Rate of patients without disease at the end of TNT and therefore not requiring surgery for at least 3 years of follow-up. Started Sep 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on MOH_2024-11-14_013511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-11-14_013511.